Tuning heavy metal compounds for anti-tumor activity: Is diversity the key to rutheniums success?

Future Medicinal Chemistry

Volumn 1, Issue 3, 2009, Pages 541-559

  Page, Simon M ^a   Boss, Sally R ^a   Barker, Paul D ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PLATINUM COMPLEX; POLYCYCLIC AROMATIC HYDROCARBON; RUTHENIUM; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DRUG DESIGN; DRUG DNA BINDING; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; COORDINATION COMPLEXES; HUMANS; NEOPLASMS; PLATINUM; RUTHENIUM;

EID: 77951519609     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.25     Document Type: Review

References (110)

1. Allardyce CS, Dyson PJ. Ruthenium in medicine: current clinical use and future prospects. Platinum Metal Rev. 45, 62-69 (2001).
2. Bruijnincx PCA, Sadler PJ. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol. 12, 197-206 (2008).
3. Lentzen O, Moucheron C, Kirsch-De Mesmaeker A. Persepctives of Ruthenium Complexes in Cancer Therapy, in Metallotherapeutic Drugs and Metal-based Diagnostic Agents: The use of Metals in Medicine. Gielen M, Tiekink ER (Eds). Wiley, Chichester, UK 359-378 (2005).
4. Rosenberg B, VanCamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698-699 (1965).
5. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem. Rev. 99, 2451-2466 (1999).
6. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307-320 (2005).
7. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7779 (2003).
8. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr. Opin. Chem. Biol. 7, 481-489 (2003).
9. Ang WH, Khalaila I, Allardyce CS, Juillerat-Jeanneret L, Dyson PJ. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc. 127, 1382-1383 (2005).
10. Schluga P, Hartinger CG, Egger A et al. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans. 1796 - 1802 (2006).
11. Petzold H, Sadler PJ. Oxidation induced by the antioxidant glutathione (GSH). Chem. Commun. (Camb.) 4413-4415 (2008).
12. Barnes KR, Kutikov A, Lippard SJ. Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. Chem. Biol. 11, 557-564 (2004).
13. Bednarski PJ, Grunert R, Zielzki M, Wellner A, Mackay FS, Sadler PJ. Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem. Biol. 13, 61-67 (2006).
14. Mackay FS, Woods JA, Moseley H et al. A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin. Chemistry Eur. J. 12, 3155-3161 (2006).
15. Sun RWY, Ma DL, Wong ELM, Che CM. Some uses of transition metal complexes as anti-cancer and anti-HIV agents. Dalton Trans. 4884-4892 (2007).
16. Sadler PJ, Shipman M. In: Biological Inorganic Chemistry: Structure and Reactivity. University Science Books, VA, USA (2006).
17. Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem. 4, 1525-1535 (2004).
18. Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium anticancer drugs. In: Metal Ions in Biolgical Systems (Volume 42). Metal Complexes in Tumor Diagnosis and as Anticancer Agents. CRC Press 323-351 (2004).
19. Anghileri LJ. In vivo inhibition of tumorgrowth by ruthenium red - its relationship with metabolism of calcium in tumor. Z. Krebsforsch. Klin. Onkol. Cancer Res. Clin. Oncol. 83, 213-217 (1975).
20. Chu AJ, Wang ZG, Nwobi OI, Beydoun S. Blockade by ruthenium red of tissue factor-initiated coagulation. Br. J. Pharmacol. 133, 659-664 (2001).
21. Keppler BK (Ed.). Metal Complexes in Cancer Chemotherapy. VCH Weinhein, NY, USA (1993).
22. Clarke MJ, Zhu FC, Frasca DR. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev. 99, 2511-2533 (1999).
23. Clarke MJ, Bitler S, Rennert D, Buchbinder M, Kelman AD. Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components. J. Inorg. Biochem. 12, 79-87 (1980).
24. Yasbin RE, Matthews CR, Clarke MJ. Mutagenic and toxic effects of ruthenium. Chem. Biol. Interact. 31, 355-365 (1980).
25. Clarke MJ. Ruthenium metallopharmaceuticals. Coord. Chem. Rev. 236, 209-233 (2003).
26. Hannon MJ. Metal-based anticancer drugs: from a past anchored in platinum postgenomic future and biology. Pure Appl. Chem. 79, 2243-2261 (2007).
27. Sava G, Pacor S, Zorzet S, Alessio E, Mestroni G. Antitumour properties of dimethylsulfoxide ruthenium(II) complexes in the Lewis lung-carcinoma system. Pharmacol. Res. 21, 617-628 (1989).
28. Sava G, Pacor S, Ceschia V, Alessio E, Mestroni G. Trans-Ru(II) dimethylsulphoxides - antineoplastic action on mouse-tumors. Pharmacol. Res. 21, 453-454 (1989).
29. Novakova O, Hofr C, Brabec V. Modification of natural, double-helical DNA by antitumor cis- and trans-[Cl2(Me2SO4)4Ru] in cell-free media. Biochem. Pharmacol. 60, 1761-1771 (2000).
30. Mahalingam V, Chitrapriya N, Fronczek FR, Natarajan K. New Ru(II)-dmso complexes with heterocyclic hydrazone ligands towards cancer chemotherapy. Polyhedron 27, 1917-1924 (2008).
31. Zorzet S, Bergamo A, Cocchietto M et al. Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of Matrigel invasion, may predict in vivoselective antimetastasis activity of ruthenium complexes. J. Pharmacol. Exp. Ther. 295, 927-933 (2000).
32. Sava G, Capozzi I, Clerici K, Gagliardi G, Alessio E, Mestroni G. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin. Exp. Metastasis 16, 371-379 (1998).
33. Sava G, Clerici K, Capozzi I et al. Reduction of lung metastasis by ImH[trans- RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors. Anticancer Drugs 10, 129-138 (1999).
34. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JHM. A Phase I and pharmacological study with imidazolium-trans-DMSO- imidazoletetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res. 10, 3717-3727 (2004).
35. Sava G, Gagliardi R, Cocchietto M et al. Comparison of the effects of the antimetastatic compound ImH[trans- RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice. Pathol. Oncol. Res. 4, 30-36 (1998).
36. Hartinger CG, Jakupec MA, Zorbas S-Seifried et al. KP1019, A new redox-active anticancer agent - preclinical development and results of a clinical Phase I Study in tumor patients. Chem. Biodivers. 5, 2140-2155 (2008).
37. Kapitza S, Jakupec MA, Uhl M, Keppler BK, Marian B. The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 226, 115-121 (2005).
38. Pongratz M, Schluga P, Jakupec MA et al. Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. J. Anal. At. Spectrom. 19, 46-51 (2004).
39. Heffeter P, Jakupec MA, Pongratz M et al. New insights into mechanisms underlying resistance against the anticancer Ru(III) compound KP1019 (FFC14a). Pharmacology 72, 154-154 (2004).
40. Barton JK, Lolis E. Chiral discrimination in the covalent binding of bis(phenanthroline) dichlororuthenium(II) to B-DNA. J. Am. Chem. Soc. 107, 708-709 (1985).
41. Barton JK. Metals and DNA - molecular left-handed complements. Science 233, 727-734 (1986).
42. Grover N, Welch TW, Fairley TA, Cory M, Thorp HH. Covalent binding of aquaruthenium complexes to DNA. Inorg. Chem. 33, 3544-3548 (1994).
43. Hotze ACG, EPL Van Der Geer, Kooijman H, Spek AL, Haasnoot JG, Reedijk J. Characterization by NMR spectroscopy, x-ray analysis and cytotoxic activity of the ruthenium(II) compounds RuL3 (PF6)2 (L=2-phenylazopyridine or o-tolylazopyridine) and RuĹ L-2́́ (PF6)2 (Ĺ, Ĺ́=2-phenylazopyridine, 2,2́-bipyridine). Eur. J. Inorg. Chem. 2648-2657 (2005).
44. Velders AH, Kooijman H, Spek AL, Haasnoot JG, De Vos D, Reedijk J. Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2- phenylazopyridine) ruthenium(II) complexes. Inorg. Chem. 39, 2966-2967 (2000).
45. Dale LD, Tocher JH, Dyson TM, Edwards DI, Tocher DA. Studies on DNA damage and induction of sos repair by novel multifunctional bioreducible compounds .2. A metronidazole adduct of a ruthenium-arene compound. Anticancer Drug Des. 7, 3-14 (1992).
46. Guichard SM, Else R, Reid E et al. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds. Biochem. Pharmacol. 71, 408-415 (2006).
47. Wang F, Chen H, Parsons S, Oswald ID, Davidson JE, Sadler PJ. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and x-ray structures of aqua adducts. Chemistry 9, 5810-5820 (2003).
48. Chen H, Parkinson JA, Morris RE, Sadler PJ. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. J. Am. Chem. Soc. 125, 173-186 (2003).
49. Allardyce CS, Dyson PJ, Ellis DJ, Heath SL. [Ru(eta6-p-cymene)Cl-2(pta)] (pta=1,3,5- triaza-7-phosphatricyclo[3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells. Chem. Commun. (Camb.) 1396-1397 (2001).
50. Scolaro C, Bergamo A, Brescacin L et al. In vitro and in vivo evaluation of ruthenium(II)- arene PTA complexes. J. Med. Chem. 48, 4161-4171 (2005).
51. Gopal YNV, Jayaraju D, Kondapi AK. Inhibition of topoisomerase ii catalytic activity by two ruthenium compounds: a liganddependent mode of action. Biochemistry 38, 4382-4388 (1999).
52. Hartinger CG, Nazarov AA, Ashraf SM, Dyson PJ, Keppler BK. Carbohydrate-metal complexes and their potential as anticancer agents. Curr. Med. Chem. 15, 2574-2591 (2008).
53. Berger I, Hanif M, Nazarov AA et al. In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chemistry 14, 9046-9057 (2008).
54. Schmitt F, Govindaswamy P, Suss G-Fink et al. Ruthenium porphyrin compounds for photodynamic therapy of cancer. J. Med. Chem. 51, 1811-1816 (2008).
55. Rajendiran V, Murali M, Suresh E, Sinha S, Somasundaram K, Palaniandavar M. Mixed ligand ruthenium(II) complexes of bis(pyrid- 2-yl)-/bis(benzimidazol-2- yl)-dithioether and diimines: study of non-covalent DNA binding and cytotoxicity. Dalton Trans. 148-163 (2008).
56. Tan CP, Liu J, Li H et al. Differences in structure, physiological stability, electrochemistry, cytotoxicity, DNA and protein binding properties between two Ru(III) complexes. J. Inorg. Biochem. 102, 347-358 (2008).
57. Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat L-Jeannerat, Dyson PJ. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg. Chem. 45, 9006-9013 (2006).
58. Tan CP, Liu J, Chen LM, Shi S, Ji LN. Synthesis, structural characteristics, DNA binding properties and cytotoxicity studies of a series of Ru(III) complexes. J. Inorg. Biochem. 102, 1644-1653 (2008).
59. Wang FY, Habtemariam A, van EPL der Geer et al. Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity. Proc. Natl Acad. Sci. USAa 102, 18269-18274 (2005).
60. Habtemariam A, Melchart M, Fernandez R et al. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem. 49, 6858-6868 (2006).
61. Dougan SJ, Habtemariam A, McHale SE, Parsons S, Sadler PJ. Catalytic organometallic anticancer complexes. Proc. Natl Acad. Sci. USA 105, 11628-11633 (2008).
62. Bugarcic T, Novakova O, Halamikova A et al. Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes. J. Med. Chem. 51, 5310-5319 (2008).
63. Bugarcic T, Habtemariam A, Stepankova J et al. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes. Inorg. Chem. 47, 11470-11486 (2008).
64. Serli B, Zangrando E, Gianferrara T et al. Is the aromatic fragment of piano-stool ruthenium compounds an essential feature for anticancer activity? The development of new Ru-II-[9]aneS3 analogues. Eur. J. Inorg. Chem. 3423-3434 (2005).
65. Dutta B, Scolaro C, Scopelliti R, Dyson PJ, Severin K. Importance of the pi-ligand: Remarkable effect of the cyclopentadienyl ring on the cytotoxicity of ruthenium PTA compounds. Organometallics 27, 1355-1357 (2008).
66. Scolaro C, Geldbach TJ, Rochat S et al. Influence of hydrogen-bonding substituents on the cytotoxicity of RAPTA compounds. Organometallics 25, 756-765 (2006).
67. Rehmann FJK, Cuffe LP, Mendoza O et al. Heteroaryl substituted ansa-titanocene anti-cancer drugs derived from fulvenes and titanium dichloride. App. Organomet. Chem. 19, 293-300 (2005).
68. Dyson PJ, Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans. 1929-1933 (2006).
69. Fisher KJ, Alyea EC, Shahnazarian N. A P-31 NMR-study of the water-soluble derivatives of 1,3,5-triaza-7-phosphaadamantane (Pta). Phosphorus Sulfur Silicon Relat. Elem. 48, 37-40 (1990).
70. Darensbourg DJ, Robertson JB, Larkins DL, Reibenspies JH. Water-soluble organometallic compounds. 7. Further studies of 1,3,5-triaza- 7-phosphaadamantane derivatives of group 10 metals, including metal carbonyls and hydrides. Inorg. Chem. 38, 2473-2481 (1999).
71. Schmitt F, Govindaswamy P, Zava O, Suss-Fink G, Juillerat-Jeanneret L, Therrien B. Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy. J. Biol. Inorg. Chem. 14, 101-109 (2009).
72. Vock CA, Renfrew AK, Scopelliti R, Juillerat-Jeanneret L, Dyson PJ. Influence of the diketonato ligand on the cytotoxicities of [Ru(eta6-p-cymene)- (R2acac)(PTA)]+ complexes (PTA=1,3,5-triaza-7- phosphaadamantane). Eur. J. Inorg. Chem. 1661-1671 (2008).
73. Loughrey BT, Healy PC, Parsons PG, Williams ML. Selective cytotoxic Ru(II) arene Cp* complex salts R-PhRuCp* X-+(-) for X = BF4-, PF6-, and BPh4. Inorg. Chem. 47, 8589-8591 (2008).
74. Bergamo A, Stocco G, Gava B et al. Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J. Pharmacol. Exp. Ther. 305, 725-732 (2003).
75. Chen H, Parkinson JA, Novakova O et al. Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers. Proc. Natl Acad. Sci. USA 100, 14623-14628 (2003).
76. Hotze ACG, Kariuki BM, Hannon MJ. Dinuclear double-stranded metallosupramolecular ruthenium complexes: potential anticancer drugs. Angew. Chem. Int. Ed. Engl. 45, 4839-4842 (2006).
77. Ribeiro G, Benadiba M, Colquhoun A, Silva DD. Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal antiinflammatory drugs: synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron 27, 1131-1137 (2008).
78. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94, 252-266 (2002).
79. Milkevitch M, Shirley BW, Brewer KJ. Mixed-metal polymetallic platinum complexes designed to interact with DNA. Inorganica Chimica Acta 264, 249-256 (1997).
80. van Houten B, Illenye S, Qu Y, Farrell N. Homodinuclear (Pt,Pt) and heterodinuclear (Ru,Pt) metal-compounds as DNA-protein cross-linking agents - potential suicide DNA lesions. Biochemistry 32, 11794-11801 (1993).
81. Herman A, Tanski JM, Tibbetts MF, Anderson CM. Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex. Inorg. Chem. 47, 274-280 (2008).
82. Allardyce CS, Dyson PJ. The interactions of low oxidation state transition metal clusters with DNA: potential applications in cancer therapy. J. Clus. Sci. 12, 563-569 (2001).
83. Therrien B, Ang WH, Cherioux F et al. Remarkable anticancer activity of triruthenium-arene clusters compared to tetraruthenium-arene clusters. J. Clus. Sci. 18, 741-752 (2007).
84. Wang FY, Weidt S, Xu JJ, Mackay CL, Langridge PRR-Smith, Sadler PJ. Identification of clusters from reactions of ruthenium arene anticancer complex with glutathione using nanoscale liquid chromatography Fourier transform ion cyclotron mass spectrometry combined with O-18-Labeling. J. Am. Soc. Mass Spectrom. 19, 544-549 (2008).
85. Therrien B, G Suss-Fink, Govindaswamy P, Renfrew AK, Dyson PJ. The "complex-in-acomplex" cations [(acac)2M subset of RU6(p-iPrC6H4Me) 6(tpt)2(dhbq)3]6+: a Trojan horse for cancer cells. Angew. Chem. Int. Ed. Engl. 47, 3773-3776 (2008).
86. Bregman H, Carroll PJ, Meggers E. Rapid access to unexplored chemical space by ligand scanning around a ruthenium center: discovery of potent and selective protein kinase inhibitors. J. Am. Chem. Soc. 128, 877-884 (2006).
87. Meggers E. Exploring biologically relevant chemical space with metal complexes. Curr. Opin. Chem. Biol. 11, 287-292 (2007).
88. Xie P, Williams DS, Atilta GE-Gokcumen et al. Structure-based design of an organoruthenium phosphatidyl-inositol-3- kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. ACS Chem. Biol. 3, 305-316 (2008).
89. Atilla-Gokcumen GE, Pagano N, Streu C et al. Extremely tight binding of a ruthenium complex to glycogen synthase kinase 3. Chembiochem. 9, 2933-2936 (2008).
90. Pascu GI, Hotze ACG, Sanchez-Cano C, Kariuki BM, Hannon MJ. Dinuclear ruthenium(II) triple-stranded helicates: Luminescent supramolecular cylinders that bind and coil DNA and exhibit activity against cancer cell lines. Angew. Chem. Int. Ed. Engl. 46, 4374-4378 (2007).
91. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem. Rev. 106, 2224-2248 (2006).
92. Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans- tetrachlorobis(1Hindazole) ruthenate(III) (KP1019 or FFC14A). J. Inorg. Biochem. 100, 891-904 (2006).
93. Smith CA, SutherlandSmith AJ, Keppler BK, Kratz F, Baker EN. Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution x-ray crystallographic structure analyses. J. Biol. Inorg. Chem. 1, 424-431 (1996).
94. Polec-Pawlak K, Abramski JK, Ferenc J et al. Application of capillary electrophoresisinductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins. J. Chromatogr. A 1192, 323-326 (2008).
95. Groessl M, Hartinger CG, Polec-Pawlak K, Jarosz M, Keppler BK. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma. Electrophoresis 29, 2224-2232 (2008).
96. Zobi F, Mood BB, Wood PA, Fabbiani FPA, Parsons S, Sadler PJ. Tagging (arene) ruthenium(II) anticancer complexes with fluorescent labels. Eur. J. Inorg. Chem. 2783-2796 (2007).
97. Kuntz ID, Chen K, Sharp KA, Kollman PA. The maximal affinity of ligands. Proc. Natl Acad. Sci. USA 96, 9997-10002 (1999).
98. Allardyce CS, Dyson PJ, Abou FR-Shakra, Birtwistle H, Coffey J. Inductively coupled plasma mass spectrometry to identify protein drug targets from whole cell systems. Chem. Commun. (Camb.) 2708-2709 (2001).
99. Wang Y, Chiu J-F. Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs. Met. Based Drugs 2008, 716329 (2008).
100. Will J, Wolters DA, Sheldrick WS. Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry. Chemmedchem. 3, 1696-1707 (2008).
101. Will J, Kyas A, Sheldrick WS, Wolters D. Identification of (eta(6)-arene) ruthenium(II) protein binding sites in E-coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of (eta(6)-pcymene) RuCl2(DMSO) to stress-regulated proteins and to helicases. J. Biol. Inorg. Chem. 12, 883-894 (2007).
102. Creus M, Pordea A, Rossel T et al. X-ray structure and designed evolution of an artificial transfer hydrogenase. Angew. Chem. Int. Ed. Engl. 47, 1400-1404 (2008).
103. Zakhary R, Poss KD, Jaffrey SR, Ferris CD, Tonegawa S, Snyder SH. Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide. Proc. Natl Acad. Sci. USA 94, 14848-14853 (1997).
104. Verma A, Hirsch DJ, Glatt CE, Ronnett GV, Snyder SH. Carbon-monoxide - a putative neural messenger. Science 259, 381-384 (1993).
105. Dioum EM, Rutter J, Tuckerman JR, Gonzalez G, Gilles-Gonzalez MA, McKnight SL. NPAS2: a gas-responsive transcription factor. Science 298, 2385-2387 (2002).
106. Boczkowski J, Poderoso JJ, Motterlini R. CO-metal interaction: vital signaling from a lethal gas. Trends Biochem. Sci. 31, 614-621 (2006).
107. Cotton FA, Wilkinson G. Advanced Inorganic Chemistry (3rd Edition). John Wiley and Sons, Canada (1972).
108. Huheey JE, Keiter EI, Keiter RL. Inorganic Chemistry: Principles of Structure and Reactivity (4th Edition). HarperCollins College Publishers, NY), USA (1993).
109. Yu B, Edstrom WC, Benach J et al. Crystal structures of catalytic complexes of the oxidative DNA/RNA repair enzyme AlkB. Nature 439, 879-884 (2006).
110. Zhang AS, Enns CA. Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J. Biol. Chem. 284, 711-715 (2009).